There are relatively many and growing efforts to find pharmacological alternatives to neurodegenerative and mental disorders, in this effort, successful trials have been carried out with the application of erythropoietin (EPO) 1-3 and similar molecules that do not induce erythropoiesis such as NeuroEPO, in which we have been working for several decades 4-7.
Unlike the EPO produced in the kidneys, the one produced by the mammalian brain does not appear in the databases of its sequencing nor does it have results of its molecular characteristics.
If we consider our brain the target of many mental disorders, it seems logical to think that we should know more about the molecular characteristics of its main components such as cerebral erythropoietin.
References
1. Sosa Testé I, J.C García Rodríguez, García JD. New goal in ischemia stroke therapy:rHu-EPO nasal application. (2006) Rev. Acta Pharmacol. Sin,2 006; 27 (Suppl 1): 97.
2. J. C. García Rodríguez and Iliana Sosa Testé. The nasal Route as a Potential Pathway for Delivery of Erythropoietin in the treatment of Acute Ischemic Stroke in Humans. (2009) TheScientificWorldJOUNAL 9,970-981. Review.
3. Yamila Rodríguez Cruz, Yuneidys Mengana Támos, Adriana Muñoz Cernuda, Nelvis Subirós Martines, Alina González-Quevedo4, Iliana Sosa Testé, and Julio César García Rodríguez. Treatment with Nasal Neuro-EPO Improves the Neurological, Cognitive, and Histological State in a Gerbil Model of Focal Ischemia. (2010) TheScientificWorldJOURNAL 10, 2288–2300.
4. Julio César García-Rodríguez and Yamila Rodríguez-Cruz The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease. Current Psychopharmacology, 2012, 1, 3; 228-232. PubMed FI:2.5
5. Yamila Rodríguez Cruz, Manon Strehaiano, Teresita Rodríguez Obaya Julio César García Rodríguez and Tangui Maurice. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease 55(2017) 231–248 DOI 10.3233/JAD-160500 IOS
6. Garzón Fernando, Rodríguez Yamila, García Julio Cesar and Rama Ramón. Neuroprotective Effects of neuro-EPO Using an In Vitro Model of Stroke. Behav. Sci. 2018, 8, 26; doi:10.3390/bs8020026.
7. Ramón Rama, Fernando Garzón, Yamila Rodríguez, Tanguí Maurice, Julio César García Rodríguez. Neuroprotective effect of Neuro-erythropoietin in neurodegenerative diseases: “Alea jacta est”. Neural Regen Res (2019) 14(9):1519-1521 Doi:10.4103/1673-5374.255968.
Thank you very much Dr. Hassan Izzeddin Sarsak
Indeed, this is really an excellent paper that I reviewed at the time and also years later.
However, this work does not answer all the questions that have arisen about the apparent functions of the EPO produced by different cells and their relationship with the onset and development of neurodegenerative processes.
Just to quote a question. Are all erythropoietin produced by neurons, astrocytes or pericytes, the same?
Always.
Julio Cesar.
Julio Cesar Garcia-Rodriguez, PhD
Emeritus academic, Cuban Academy of Sciences
Full professor and senior researcher
CENPALAB, National Center for Animal Breeding
BioCubaFarma
Havana, Cuba